About Me
Eric Wexler, M.D., Ph.D.
I am a board-certified physician and scientist recognized for expertise in psychopharmacology and neuropsychiatry, and I accept the most challenging cases of altered mood, impulse control, and cognition.
For the past two decades I have specialized in caring for the most treatment-resistant patients with bipolar disorder, schizophrenia, and ADHD. I have substantial experience managing complex neuropsychiatric syndromes, particularly in individuals with a coexisting neurologic, rheumatologic, or medical illness, and I have published extensively in developmental neurobiology, neuropharmacology, and neurogenetics. I currently serve as medical director of California OnTrack and accept new patients seeking evaluation, treatment, or second opinions, as well as referrals for forensic consultation.
Clinical Expertise
- Bipolar Affective Disorder
- Schizophrenia & First-Episode Psychosis
- Treatment-Resistant Depression
- Impulse Control Disorders
- Obsessive-Compulsive Disorder (OCD)
- Attention Deficit-Hyperactivity Disorder (ADHD)
- Neuropsychiatry & Neurodegenerative Disease
- Forensic Psychiatry & Medical-Legal Evaluation
Biography
Dr. Wexler is a recognized expert in psychopharmacology and neuropsychiatry who accepts the most challenging cases of altered mood, impulse control, and cognition. For the past two decades he has specialized in caring for the most treatment-resistant patients suffering from bipolar disorder, schizophrenia, and ADHD. He is the founder of Lucidity Behavioral Health and currently serves as medical director of California OnTrack, an intensive coordinated specialty care program for adolescents and adults experiencing either first-episode or chronic psychosis.
Early in his academic career he graduated Phi Beta Kappa from Vassar College with a degree in biochemistry. During medical school at the Albert Einstein College of Medicine he undertook research into nerve cell development and neurotransmitter function, for which he was awarded both a medical degree (M.D.) and a doctorate in neurobiology (Ph.D.). He next completed his residency in the Department of Psychiatry and Behavioral Sciences at Stanford University. He received his primary psychotherapy training with Dr. David Burns, best-selling author and an early popularizer of cognitive-behavioral therapy (CBT), and with C. Barr Taylor, author of the APA textbook on evidence-based psychiatry.
He then pursued specialized fellowship training in psychopharmacology and neuronal regeneration at Stanford under the auspices of Dr. Alan Schatzberg, former American Psychiatric Association president and coauthor of the official APA textbook of psychopharmacology. During this period he also served as an attending physician in the emergency department of San Francisco General Hospital/UCSF. He later completed a research fellowship in neurobehavioral genetics at UCLA before joining the full-time academic faculty at the UCLA David Geffen School of Medicine, in the division of geriatric psychiatry and the center for neurobehavioral genetics. Dr. Wexler subsequently entered private practice and later served as medical director for Resilience Treatment Centers prior to founding Lucidity.
Prior to entering private practice, Dr. Wexler, a board-certified psychiatrist and qualified medical examiner, was engaged in both clinical care and basic science research at the UCLA School of Medicine. There his clinical activities included an outpatient clinic emphasizing mood and impulse control disorders, psychiatric consultation for patients with rare inherited or autoimmune forms of neurodegeneration (including patients of the UCLA Huntington's Disease Center of Excellence), and attending on the inpatient geriatric psychiatry unit at the UCLA-Resnick Neuropsychiatric Hospital.
Complementing these clinical efforts, his research agenda focused on understanding the molecular mechanisms underlying the effectiveness of common mood stabilizers such as lithium; developing novel experimental models of neuropsychiatric disease (e.g. dementia or autism), primarily using human neural stem cells; and developing and applying novel network ("big data") analytic methods to the problem of understanding the signals that govern early nerve cell development and how these contribute to brain dysfunction. In addition, he has provided discreet consultation services to individuals and organizations in the television, print media, legal, and investment banking communities, including work as a technical expert on bipolar disorder and psychosis for Homeland (Fox) and Dexter (Showtime), a clinical consultant to Cochrane Reviews in the psychopharmacology of bipolar affective disorder, and a consulting expert on international treatment guidelines for Huntington's disease.
Board Certification & Licensure
Diplomate in Psychiatry #53505, American Board of Psychiatry & Neurology (2004–present). California Medical License #A69685. DEA #BW6493631 / XW6493631 (Center for Substance Abuse Treatment). Qualified Medical Examiner, California (2014–present).
Training
M.D. and Ph.D. in Neuroscience, Albert Einstein College of Medicine. Psychiatry residency, Stanford University Medical Center. A.B. Biochemistry, Phi Beta Kappa, Vassar College.
Research Fellowships
Postdoctoral fellowships in psychopharmacology and neuronal regeneration (Stanford), aging research (Palo Alto VA / MIRECC), and neurobehavioral genetics (UCLA). NIH, NARSAD, CIRM, and J.D. French Foundation funded principal investigator.
Academic Appointment
Former Assistant Professor (2006–2013), Semel Institute, Center for Neurobehavioral Genetics and Division of Geriatric Psychiatry, David Geffen School of Medicine at UCLA.
Curriculum Vitae
Download full CV (PDF)Current Professional Activities
- 2022–present
- Medical Director, PAND Health & California OnTrack, an expanded coordinated specialty care (CSC+) program treating first-episode psychosis and chronic schizophrenia, and a developer of clinical training materials (featured in The Wall Street Journal, 12/21/2024).
- 2022–present
- Consulting Psychiatrist, Los Angeles Clippers
- 2014–present
- Qualified Medical Evaluator (QME, California) and Independent Medical Evaluator
- 2012–present
- Private Practice, Santa Monica, evidence-based treatment of a broad range of psychiatric disorders, with emphasis on complex neuropsychiatric syndromes.
- 2012–present
- Forensic Consulting Expert
- 2015–2022
- Medical Director, Resilience Treatment Centers, CBT/DBT-based residential and intensive outpatient care for bipolar disorder, borderline personality disorder, schizophrenia, and treatment-resistant depression.
Education
- 2004–2006
- Postdoctoral Fellow, Neurobehavioral Genetics, University of California, Los Angeles
- 2003–2004
- Postdoctoral Fellow, Aging Research, Palo Alto Veterans Hospital / MIRECC
- 2002–2004
- Postdoctoral Fellow, Psychopharmacology Research, Departments of Psychiatry and Neurosurgery, Stanford University
- 1998–2002
- Resident, Department of Psychiatry & Behavioral Sciences, Stanford University Medical Center, Stanford, CA
- 1989–1998
- M.D., Albert Einstein College of Medicine, Bronx, NY
- 1991–1998
- Ph.D. Neuroscience, Albert Einstein College of Medicine, Bronx, NY
- 1985–1989
- A.B. Biochemistry, Vassar College, Poughkeepsie, NY
Past Academic Appointments
- 2006–2013
- Assistant Professor, Semel Institute: Center for Neurobehavioral Genetics and Division of Geriatric Psychiatry, David Geffen School of Medicine, UCLA
- 2004–2006
- Clinical Instructor, Department of Psychiatry and Behavioral Sciences, David Geffen School of Medicine, UCLA
- 2002–2004
- Attending Psychiatrist, Psychiatric Emergency Services, San Francisco General Hospital, UCSF
- 2000–2002
- Psychiatrist, Schuman-Liles Clinic, Fremont, CA
Past Clinical Activities
- 2006–2012
- Geriatric Psychiatry Attending, Resnick Neuropsychiatric Hospital, UCLA
- 2006–2012
- Attending Psychiatrist, UCLA Huntington's Disease Center of Excellence, Department of Neurology
- 2006–2012
- Attending Psychiatrist, Neurogenetics Clinic, Department of Neurology, UCLA
- 2005–2012
- Attending, adult outpatient psychiatry clinic, Department of Psychiatry and Behavioral Sciences, UCLA
- 2005–2006
- Consultation/Liaison Attending Psychiatrist, organ transplantation and general medical services, UCLA Hospital
Professional Memberships
- 2022–present
- Psychiatric Rehabilitation Association (Academy for Psychiatric Rehabilitation and Recovery)
- 2019–present
- American Society of Clinical Psychopharmacology (Program Committee, Scientific Reviewer)
- 2018–present
- American Neuropsychiatric Association (Standards & Ethics Committee, Forensics SIG)
- 2004–present
- American Psychiatric Association
Grants, Awards & Honors
- 2024–2026
- Children and Youth Behavioral Health Initiative ($2,000,000), CSC for First Episode of Psychosis Implementation. Role: Principal Director.
- 2011–2014
- California Institute of Regenerative Medicine ($16,300), Regeneration of Functional Human Corneal Epithelial Progenitor Cells. Role: Co-investigator.
- 2008–2012
- J.D. French Foundation for Alzheimer's Research ($400,000), Transgenic human neural stem cells as a model of Alzheimer's dementia. Role: Principal Investigator.
- 2006–2011
- NIH NIMH-K08MH74362 ($776,500), Role of Wnt Signaling in Adult Hippocampal Progenitor Cell Development. Role: Principal Investigator.
- 2002–2006
- National Alliance for Research on Schizophrenia and Depression ($60,000), Effects of Lithium/Wnt on Adult Neural Stem Cells. Role: Principal Investigator.
- 2002
- Pfizer Neuroscience Resident of the Year Award; Medical Scientist Training Program.
Selected Publications
- Quoted in “One Surprising Psychosis Treatment That Works: Learning to Live With the Voices,” Julie Wernau, The Wall Street Journal, Dec. 21, 2024 (front page; describes outcomes at California OnTrack).
- Burch J, Wexler E. Aripiprazole compared with other atypical antipsychotics in schizophrenia. Cochrane Clinical Answers, 2017.
- Hanners NW, … Wexler EM, Konopka G, Schoggins JW. Western Zika virus in human fetal neural progenitors persists long term with partial cytopathic and limited immunogenic effects. Cell Reports, 2016.
- Stein JL, … Wexler EM, Geschwind DH. A quantitative framework to evaluate modeling of cortical development by neural stem cells. Neuron, 2014.
- Wexler E. Clinical neurogenetics: behavioral management of inherited neurodegenerative disease. Neurologic Clinics, 2013.
- Konopka G, Wexler E, et al. Modeling the functional genomics of autism using human neurons. Molecular Psychiatry, 2012 (cover article).
- Wexler EM, Geschwind DH. DISC1: a schizophrenia gene with multiple personalities. Neuron, 2011.
- Wexler EM, et al. Genome-wide analysis of a Wnt1-regulated transcriptional network implicates neurodegenerative pathways. Science Signaling, 2011.
- Wexler EM, Geschwind DH, Palmer TD. Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Molecular Psychiatry, 2008 (cover article).
Editorial and review service: program and seminar reviewer, American Society of Clinical Psychopharmacology (2022–present); research and development grant reviewer, Neurobiology Panel, Department of Veterans Affairs (2012–2017); ad hoc reviewer (2002–2016) for Cell, Cerebral Cortex, Neuron, Journal of Geriatric Psychiatry, Molecular & Cellular Neuroscience, Biological Psychiatry, Neurobiology of Disease, Clinical Psychiatry, and Stem Cells.
